Acquisitions (Tables)

12 Months Ended

Dec. 31, 2021

2020 Acquisitions

Acquisitions

Schedule of Components and fair value allocation of the consideration transferred in connection with acquisitions

In addition to the acquisitions noted above, in 2020 the Company completed various other acquisitions that complemented the Company’s existing product offerings. The following table reflects the consideration transferred and the respective reportable segment for these acquisitions (in millions):

Name of Acquisition	Date Acquired		Segment		Total Consideration		Cash Consideration
SmartTip B.V.		April 1, 2020		BSI Nano	$	3.1	$	2.4
Integrated Proteomics Applications, Inc.		August 7, 2020		BSI Life Science		3.0		3.0
					$	6.1	$	5.4

2021 Acquisitions

Acquisitions

Schedule of consideration transferred and the respective reporting segment for each acquisition

	SCI Instruments			Molecubes NV
Segment	BSI Nano			BSI Life Science
Consideration Transferred:
Cash paid	$	28.0		$	21.1
Fair value of contingent consideration		1.0			0.4
Working capital adjustment		(0.6	)		—
Total consideration transferred	$	28.4		$	21.5
Allocation of Consideration Transferred:
Cash	$	—		$	1.1
Accounts receivable		—			1.2
Inventories		1.0			1.5
Other current assets		—			0.3
Property, plant and equipment		—			0.1
Intangible assets:
Technology		7.1			3.4
Customer relationships		6.4			2.4
Trade name		0.4			0.5
Backlog		1.2			0.1
Goodwill		12.6			14.1
Deferred taxes		—			(1.6	)
Liabilities assumed		(0.3	)		(1.6	)
Total consideration allocated	$	28.4		$	21.5

Molecubes NV [Member]

Acquisitions

Schedule of Components and fair value allocation of the consideration transferred in connection with acquisitions

In addition to the SCI and Molecubes acquisitions, in 2021 the Company completed various other acquisitions accounted for under the acquisition method that complemented the Company’s existing product offerings. The following table reflects the consideration transferred and the respective reportable segment for these acquisitions (in millions):

Name of Acquisition	Date Acquired		Segment		Total Consideration		Cash Consideration
Creative Instruments		July 1, 2021		BSI Life Science	$	1.0	$	1.0
SVXR, Inc		September 9, 2021		BSI Nano		13.4		11.9
					$	14.4	$	12.9

In addition to the acquisitions noted above, in 2021 the Company completed minority investments that complemented the Company’s existing product offerings. The following table reflects the consideration transferred and the respective reportable segment for the acquisitions (in millions):

Name

Acquisition / Investment

Financial Statement Classification

Date Acquired

Segment

Total Consideration

Cash Consideration

Glycopath Inc.

Investment

Other long-term assets

February 18, 2021

BSI Life Science

$

2.0

$

2.0

IonPath Inc.

Investment

Other long-term assets

March 18, 2021

BSI Life Science

2.0

2.0

Olaris, Inc.

Investment

Other long-term assets

September 23, 2021

BSI Life Science

0.5

0.5

$

4.5

$

4.5

Sci Instruments [Member]

Acquisitions

Schedule of consideration transferred and the respective reporting segment for each acquisition

The components and fair value allocation of the consideration transferred in connection with the acquisition are as follows (in millions):

Consideration Transferred:
Cash paid	$	24.4
Contingent consideration		0.5
Cash acquired		(0.5	)
Working capital adjustment		0.3
Total consideration transferred	$	24.7
Allocation of Consideration Transferred:
Inventories	$	1.1
Accounts receivable		1.2
Other current and non-current assets		1.0
Property, plant and equipment		0.9
Operating lease assets		0.3
Intangible assets:
Technology		5.7
Customer relationships		6.1
Trade name		0.7
Backlog		0.3
Goodwill		12.0
Deferred taxes, net		(2.0	)
Liabilities assumed		(2.6	)
Total consideration allocated	$	24.7